@article{24e158d85b2041f5a28b76147c794990,
title = "Alternating Thalamic Deep Brain Stimulation for Essential Tremor: A Trial to Reduce Habituation",
abstract = "Background: DBS in the ventral intermediate nucleus (VIM) of the thalamus has been a revolutionary treatment for patients with essential tremor (ET) by reducing tremor. Unfortunately, some patients develop habituation to DBS and thus experience reduced efficacy and loss of tremor control. There are no standardized methods of addressing habituation to DBS. We propose alternating stimulation patterns as a way to reduce habituation. Methods: This was a randomized, placebo-controlled trial for patients with VIM DBS for ET. Patients were randomized to either experimental treatment arm of alternating stimulation patterns on a weekly basis or standard care arm of continuous stimulation settings for 12 weeks. Primary outcome was change in the performance subscale of The Essential Tremor Rating Assessment Scale (TETRAS), which was performed at initial visit and 12-week follow-up. Secondary outcome included change in the activities of daily living subscale of TETRAS. Results: Twenty-two patients were enrolled in the trial, and 16 were analyzed at follow-up. Experimental treatment subjects displayed sustained tremor control compared to standard care, as measured by the change in TETRAS performance subscale (–0.6 vs. 6.7 point change, respectively) with a 7.3 difference between the arms (P = 0.006). Conclusion: Alternating stimulation patterns on a weekly basis for ET patients with VIM DBS reduced habituation in this pilot study. This study suggests that exposure to different stimulation groups may maintain better tremor control compared to constant stimulation parameters.",
keywords = "VIM, deep brain stimulation, essential tremor, habituation",
author = "Mara Seier and Amie Hiller and Joseph Quinn and Charles Murchison and Matthew Brodsky and Shannon Anderson",
note = "Funding Information: Ethical Compliance Statement: This study was registered on ClinicalTrials.gov (NCT02947841). The study protocol, informed consent, and other study documents were reviewed and approved by OHSU{\textquoteright}s institutional review board. All patients provided written informed consent. We confirm that we have read the Journal{\textquoteright}s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: M.B. received funding from Medtronic for an unrelated research project. M.S. received funding for this project from N. L. Tartar Trust Research Fellowship, Oregon Health and Sciences University, Department of Medicine. Financial Disclosures for previous 12 months: M.S. is employed by the University of Nebraska Medical Center and has no other financial disclosures. A.H. is employed by the VA Portland Health Care System and OHSU and has funding from The Pacific Northwest Udall Center, Michael J. Fox Foundation, NeuroNEXT/Azevan Pharmaceuticals, Prothena Biosciences, and AbbVie. J.Q. is employed by the VA Portland Health Care System and OHSU and has funding from the NIH/NINDS and NIH/NCCIH. C.M. is currently employed by the University of Alabama at Birmingham and formally by OHSU and has funding from the NIH/NINDS, NIH/NCCIH, Allen Award, and the Department of Defense. M.B. is employed by OHSU and has funding from Medtronic and Roche. He has served on advisory board/honoraria for Abbot and Acadia. S.A. is employed by OHSU and has no other financial disclosures. Publisher Copyright: {\textcopyright} 2018 International Parkinson and Movement Disorder Society",
year = "2018",
month = nov,
day = "1",
doi = "10.1002/mdc3.12685",
language = "English (US)",
volume = "5",
pages = "620--626",
journal = "Movement Disorders Clinical Practice",
issn = "2330-1619",
publisher = "John Wiley and Sons Ltd",
number = "6",
}